365 related articles for article (PubMed ID: 26785287)
1. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Roboz GJ; Montesinos P; Selleslag D; Wei A; Jang JH; Falantes J; Voso MT; Sayar H; Porkka K; Marlton P; Almeida A; Mohan S; Ravandi F; Garcia-Manero G; Skikne B; Kantarjian H
Future Oncol; 2016 Feb; 12(3):293-302. PubMed ID: 26785287
[TBL] [Abstract][Full Text] [Related]
2. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H
J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540
[TBL] [Abstract][Full Text] [Related]
3. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
[TBL] [Abstract][Full Text] [Related]
4. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
[TBL] [Abstract][Full Text] [Related]
5. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
[TBL] [Abstract][Full Text] [Related]
6. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR; Scott BL; Boyd T; Garcia-Manero G
Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
[TBL] [Abstract][Full Text] [Related]
7. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
Ivanov V; Yeh SP; Mayer J; Saini L; Unal A; Boyiadzis M; Hoffman DM; Kang K; Addo SN; Mendes WL; Fathi AT
Future Oncol; 2022 Aug; 18(26):2879-2889. PubMed ID: 35852098
[TBL] [Abstract][Full Text] [Related]
8. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Kipp D; H Wei A
Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
Griffin PT; Komrokji RS; De Castro CM; Rizzieri DA; Melchert M; List AF; Lancet JE
Am J Hematol; 2015 Sep; 90(9):796-9. PubMed ID: 26089240
[TBL] [Abstract][Full Text] [Related]
10. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
de Lima M; Oran B; Champlin RE; Papadopoulos EB; Giralt SA; Scott BL; William BM; Hetzer J; Laille E; Hubbell B; Skikne BS; Craddock C
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2017-2024. PubMed ID: 29933073
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.
Wei AH; Roboz GJ; Dombret H; Dohner H; Schuh AC; Montesinos P; Selleslag D; Bondarenko SN; Prebet T; Lai Y; Skikne B; Beach CL; Ravandi F
Haematologica; 2023 Oct; 108(10):2820-2825. PubMed ID: 36951156
[No Abstract] [Full Text] [Related]
13. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
Wei AH; Döhner H; Sayar H; Ravandi F; Montesinos P; Dombret H; Selleslag D; Porkka K; Jang JH; Skikne B; Beach CL; Prebet T; Zhang G; Risueño A; Ugidos M; See WL; Menezes D; Roboz GJ
Am J Hematol; 2023 Apr; 98(4):E84-E87. PubMed ID: 36655608
[No Abstract] [Full Text] [Related]
15. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Huls G; Chitu DA; Havelange V; Jongen-Lavrencic M; van de Loosdrecht AA; Biemond BJ; Sinnige H; Hodossy B; Graux C; Kooy RVM; de Weerdt O; Breems D; Klein S; Kuball J; Deeren D; Terpstra W; Vekemans MC; Ossenkoppele GJ; Vellenga E; Löwenberg B;
Blood; 2019 Mar; 133(13):1457-1464. PubMed ID: 30630862
[TBL] [Abstract][Full Text] [Related]
16. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
Blum W; Sanford BL; Klisovic R; DeAngelo DJ; Uy G; Powell BL; Stock W; Baer MR; Kolitz JE; Wang ES; Hoke E; Mrózek K; Kohlschmidt J; Bloomfield CD; Geyer S; Marcucci G; Stone RM; Larson RA;
Leukemia; 2017 Jan; 31(1):34-39. PubMed ID: 27624549
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.
Jen EY; Wang X; Li M; Li H; Lee SL; Ni N; Przepiorka D; Vallejo J; Leong R; Ma L; Gehrke BJ; McLamore S; Theoret MR; de Claro RA
Clin Cancer Res; 2022 Jul; 28(14):2989-2993. PubMed ID: 35325108
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.
Zhu J; Wu Q; Wang J; Niu T
Expert Rev Hematol; 2022 Apr; 15(4):375-382. PubMed ID: 35437111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]